{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T21:26:47Z","timestamp":1781904407022,"version":"3.54.5"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970142"],"award-info":[{"award-number":["81970142"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970142"],"award-info":[{"award-number":["81970142"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970142"],"award-info":[{"award-number":["81970142"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the National Clinical Research Center for Hematologic Disease","award":["H220559"],"award-info":[{"award-number":["H220559"]}]},{"name":"the National Clinical Research Center for Hematologic Disease","award":["H220559"],"award-info":[{"award-number":["H220559"]}]},{"name":"the National Clinical Research Center for Hematologic Disease","award":["H220559"],"award-info":[{"award-number":["H220559"]}]},{"name":"the National Clinical Research Center for Hematologic Disease","award":["H220559"],"award-info":[{"award-number":["H220559"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00277-024-06027-w","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T08:01:42Z","timestamp":1728892902000},"page":"4643-4648","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"103","author":[{"given":"Yiyan","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengli","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"issue":"25","key":"6027_CR1","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMra2113347","volume":"386","author":"R Fo\u00e0","year":"2022","unstructured":"Fo\u00e0 R, Chiaretti S (2022) Philadelphia chromosome\u2013positive Acute Lymphoblastic Leukemia. N Engl J Med 386(25):2399\u20132411","journal-title":"N Engl J Med"},{"issue":"3","key":"6027_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/ajh.26816","volume":"98","author":"H Kantarjian","year":"2023","unstructured":"Kantarjian H, Short NJ, Jain N et al (2023) Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol 98(3):493\u2013501","journal-title":"Am J Hematol"},{"issue":"1","key":"6027_CR3","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N et al (2023) Ponatinib and Blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol 10(1):e24\u2013e34","journal-title":"Lancet Haematol"},{"key":"6027_CR4","doi-asserted-by":"crossref","unstructured":"Jiang Q, Li Z, Qin Y et al (2022) Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial. J Hematol Oncol. 15(1)","DOI":"10.1186\/s13045-022-01334-z"},{"issue":"4","key":"6027_CR5","first-page":"469","volume":"82","author":"S Dhillon","year":"2022","unstructured":"Dhillon S, Olverembatinib (2022) First Approval Drugs 82(4):469\u2013475","journal-title":"First Approval Drugs"},{"key":"6027_CR6","doi-asserted-by":"crossref","unstructured":"Fan S, Wang L, Lu Y, Li Z Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosome\u2013positive acute lymphoblastic leukemia: two-case report. Ann Hematol. Published online 2023.","DOI":"10.1007\/s00277-023-05519-5"},{"issue":"9","key":"6027_CR7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.clml.2023.04.012","volume":"23","author":"X Li","year":"2023","unstructured":"Li X, Zhang J, Liu F et al (2023) Olverembatinib Treatment in Pediatric patients with relapsed Philadelphia-chromosome-positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 23(9):660\u2013666","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6027_CR8","doi-asserted-by":"crossref","unstructured":"Liu X, Wang G, Yan X et al (2019) Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci. 9(1)","DOI":"10.1186\/s13578-019-0351-6"},{"issue":"Supplement 1","key":"6027_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/blood-2022-162387","volume":"140","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Koller PB, Oehler VG et al (2022) Olverembatinib (HQP1351) overcomes Ponatinib Resistance in patients with heavily Pretreated\/Refractory chronic myeloid leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph\u2009+\u2009ALL). Blood 140(Supplement 1):200\u2013202","journal-title":"Blood"},{"key":"6027_CR10","unstructured":"Jabbour E et al Presented at 2024EHA. Abstract: P722"},{"key":"6027_CR11","doi-asserted-by":"crossref","unstructured":"Jabbour E, Kantarjian HM, Aldoss I et al Ponatinib vs Imatinib in Frontline Philadelphia chromosome-positive Acute Lymphoblastic Leukemia: a Randomized Clinical Trial. JAMA. Published online 2024.","DOI":"10.1001\/jama.2024.4783"},{"key":"6027_CR12","doi-asserted-by":"crossref","unstructured":"Short NJ, Jabbour E, Jain N et al (2023) A phase II trial of Ponatinib and Blinatumomab in adults with newly diagnosed Philadelphia Chromosome-. Positive Acute Lymphoblastic Leukemia (Ph\u2009+\u2009ALL).","DOI":"10.1200\/JCO.2023.41.16_suppl.e19013"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06027-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06027-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06027-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T09:30:16Z","timestamp":1730712616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06027-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":12,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["6027"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06027-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the First Affiliated Hospital Ethics Committee of Soochow University. Written informed consent was obtained from every patient in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No conflict of interests declared.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}